Poster-Disease-modifying Therapy
October 25, 2021
Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19
Background: Several integrated analyses have reported on the safety of cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years...
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Efficacy and Safety of Eculizumab in AQP4+ Neuromyelitis Optica Spectrum Disorder
Background: Neuromyelitis optica spectrum disorder (NMOSD) relapses can cause significant and irreversible neurologic disability. In...
Poster-Disease-modifying Therapy
October 25, 2021
Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS
Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...
Poster-Disease-modifying Therapy
October 25, 2021
Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study
Background: The action of cladribine tablets (CladT) on immune cells may be key for both onset and durability of its effect in people with...
Poster-Disease-modifying Therapy
October 25, 2021
Click-MS: Cladribine Tablets in Patients with Relapsing Multiple Sclerosis after Suboptimal Response to Prior Injectable Disease-Modifying Therapy (Interim Analysis 1)
Background: The efficacy and safety of cladribine tablets 3.5 mg/kg (cumulative dose over 2 years) have been shown in patients with...
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years
Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...
Poster-Disease-modifying Therapy
October 25, 2021
Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study
Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...
Poster-Disease-modifying Therapy
October 25, 2021
Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis
Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor with dual mode of action, targeting B cells and...
Platform-Disease Modifying Therapies
October 25, 2021
Postpartum Relapse Rates in Women with Relapsing Multiple Sclerosis and the Impact of Disease-Modifying Drugs: A Systematic Review
Background: It is widely accepted that relapses of multiple sclerosis (MS) decrease during pregnancy; however, studies show an increased...
October 25, 2021
Development and Usability Testing of a Patient-Based Digital Tool to Detect Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire
Background: The validated physician-completed MSProDiscussTM tool facilitates physician-patient interaction in evaluating early signs of...